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rel
Li
MaBACKGROUND There are currently inadequate data on whether “late restenosis” occurs after paclitaxel-coated balloon
(PCB) angioplasty for in-stent restenosis (ISR) lesions.
OBJECTIVES To evaluate the long-term safety and efﬁcacy of PCB angioplasty, we investigated serial clinical and
angiographic outcomes after PCB angioplasty for ISR lesions.
METHODS Between September 2008 and December 2012, PCB angioplasty was performed in 468 patients with 550
ISR lesions (bare-metal stent restenosis [BMS-ISR]: 114 lesions, drug-eluting stent restenosis [DES-ISR]: 436 lesions).
Two serial angiographic follow-ups were routinely planned for the patients (at 6 and 18 months after the procedure).
RESULTS Early follow-up (6 months) angiography was performed for 488 lesions (89%), and recurrent restenosis
occurred in 13 lesions (13.0%) in the BMS-ISR group and in 82 lesions (21.1%) in the DES-ISR group. Target lesion
revascularization was performed for 7 lesions (7.0%) in the BMS-ISR group and 54 lesions (13.9%) in the DES-ISR group.
Late follow-up (18 months) angiography was performed for 377 (88%) of the remaining 427 lesions (excluding target
lesion revascularization lesions), and late restenosis was found in 2 lesions (2.5%) in the BMS-ISR group and 50 lesions
(16.8%) in the DES-ISR group. Delayed late lumen loss was signiﬁcantly larger in the DES-ISR group. Previous stent
size #2.5 mm, percentage diameter stenosis after the procedure, and in-stent occlusion lesion were independent
predictors of early restenosis. DES-ISR, percentage diameter stenosis at early follow-up, and hemodialysis were
independent predictors of late restenosis.
CONCLUSIONS Late restenosis occurs after PCB angioplasty for DES-ISR lesions. (J Am Coll Cardiol 2015;66:14–22)
© 2015 by the American College of Cardiology Foundation.R ecently, paclitaxel-coated balloon (PCB) an-gioplasty has emerged as a potential alterna-tive to the current treatment for in-stent
restenosis (ISR). However, there are concerns about
the long-term efﬁcacy and safety of PCB angioplasty.
There are currently inadequate data on whether “late
restenosis” occurs after PCB angioplasty for bare-
metal stent restenosis (BMS-ISR) and drug-eluting
stent restenosis (DES-ISR). Treatment of BMS-ISR
with a PCB persistently has been shown to reduce
repeat revascularization during long-term follow-upm the Department of Cardiology, Kurashiki Central Hospital, Kurashiki,
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sten to this manuscript’s audio summary by JACC Editor-in-Chief Dr. Val
nuscript received March 4, 2015; revised manuscript received April 30, 2(1,2). A recent study has shown that DES-ISR was asso-
ciated with poorer outcomes than those of BMS-ISR af-
ter treatment with a PCB (3). To evaluate the safety and
efﬁcacy of PCB angioplasty, we investigated serial
clinical and angiographic outcomes after PCB angio-
plasty for ISR lesions (BMS-ISR and DES-ISR).
METHODS
PATIENT POPULATION. This study was a retrospec-
tive analysis of a prospective protocol including serialJapan. The authors have reported that they have no
entin Fuster.
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AB BR E V I A T I O N S
AND ACRONYM S
BMS = bare-metal stent(s)
BMS-ISR = bare-metal stent
restenosis
CI = conﬁdence interval(s)
DES = drug-eluting stent(s)
DES-ISR = drug-eluting stent
restenosis
ISR = in-stent restenosis
OR = odds ratio
PCB = paclitaxel-coated
balloon
TLR = target lesion
cularization
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15angiographic follow-up. Between September 2008
and December 2012, 1,123 ISR lesions were treated
with percutaneous coronary intervention (PCB or
DES), and PCB angioplasty was performed in 550 ISR
lesions in 468 patients (BMS-ISR: 114 lesions, DES-
ISR: 436 lesions). SeQuent Please paclitaxel-coated
balloon catheter (B. Braun Melsungen AG, Vascular
Systems, Berlin, Germany) was used in this study.
The exclusion criteria were recurrent lesions after
PCB angioplasty for ISR, lesions located in bypass
conduits, and bailout stenting after PCB angioplasty
due to major dissection. The study was done in
accordance with the provisions of the Declaration of
Helsinki and local regulations. All patients provided
informed consent for both the procedure and subse-
quent data collection and analysis for research pur-
poses, and the study was approved by the
institutional ethics committee.SEE PAGE 34INTERVENTIONAL PROCEDURE. All patients were
pre-treated with aspirin (100 mg daily) and ticlopi-
dine (200 mg daily)/clopidogrel (75 mg daily). Aspirin
and ticlopidine/clopidogrel treatment was recom-
mended for at least 6 months. The procedures were
performed according to standard clinical guidelines.
In all cases, the interventional strategy and the use
of adjunctive devices and pharmacotherapy were at
the discretion of the operator. Pre-dilation was per-
formed for all ISR lesions. The length of the PCB was
chosen to overlap the lesion by at least 2 mm at the
proximal and distal margins. The recommended
inﬂation time for the PCB was 60 s.
FOLLOW-UP AND DEFINITIONS. Two serial angio-
graphic follow-ups were routinely planned for the
patients. Early follow-up was planned at 6 months
after the procedure, and late follow-up was planned
at 18 months after the procedure. The follow-up
angiogram was obtained earlier if clinically indi-
cated. Follow-up angiography performed at 5 to
12 months was considered early follow-up. Follow-up
angiography performed at 12 to 24 months was con-
sidered late follow-up. When recurrent restenosis
occurred within 5 months, it was included in early
follow-up results. Clinical follow-up was performed
by telephone contact or ofﬁce visit. Binary restenosis
at follow-ups was deﬁned as stenosis occupying
>50% of the diameter. Late restenosis was deﬁned
as diameter stenosis $50% at late follow-up in
lesions of <50% diameter stenosis at early follow-up.
Target lesion revascularization (TLR) was deﬁned as
any repeat percutaneous coronary intervention or
aortocoronary bypass surgery because of restenosis(diameter stenosis $50%) associated with
symptoms or objective signs of ischemia
(stress electrocardiogram, myocardial perfu-
sion imaging, or fractional ﬂow reserve). We
applied Academic Research Consortium
criteria for deﬁnite stent thrombosis for
adjudication of target lesion thrombosis.
ANGIOGRAPHIC ANALYSIS. Quantitative coro-
nary angiographic analysis was performed
using QCA-CMS (Medis Medical Imaging Sys-
tems, Leiden, the Netherlands). All angio-
grams were analyzed in a random sequence
by 2 experienced observers who were blinded
to the clinical characteristics of patients.
Coronary angiograms were obtained in mul-
tiple views after intracoronary nitrate administration.
Reference diameter, minimal lumen diameter, per-
centage diameter stenosis, and lesion length were
measured before and after intervention and at follow-
up. Acute gain was deﬁned as minimal lumen diam-
eter immediately after the procedure minus that at
baseline. Late lumen loss was deﬁned as minimal
lumen diameter immediately after the procedure
minus that at angiographic follow-up. Delayed late
lumen loss was deﬁned as minimal lumen diameter
at early follow-up minus that at late follow-up. Pro-
gression case was deﬁned as a case of delayed late
lumen loss >0 mm. Measurements were done at the
target lesion treated by a PCB within 5 mm proximal
and distal to the treated area. ISR was classiﬁed
according to the Mehran classiﬁcation (4). A multi-
focal lesion was classiﬁed as non-focal-type reste-
nosis lesion. Stent fracture was angiographically
deﬁned at the use of a PCB.
STUDY ENDPOINTS. The efﬁcacy endpoint included
late lumen loss, rate of binary restenosis, and rate of
TLR at follow-up. The safety endpoint included major
adverse cardiac events and a composite of cardiac
death, myocardial infarction, or target lesion throm-
bosis at follow-up. The efﬁcacy endpoints were
evaluated on a per-lesion basis. The safety endpoints
were evaluated on a per-patient basis.
STATISTICAL ANALYSIS. Continuous variables are
expressed as mean  SD. Values are shown as
numbers with relative percentage or SD. For contin-
uous data, the groups were compared with the Stu-
dent t test or Wilcoxon rank-sum test on the basis of
the distribution. Categorical variables were compared
using the chi-square test. Risk factors of early reste-
nosis and late restenosis after PCB angioplasty were
analyzed separately. A multivariable logistic regres-
sion model instead of a Cox proportional hazard
model was used to identify independent risk factors
revas
TABLE 1 Baseline Clinical, Angiographic, and Procedural Characteristics
Overall BMS-ISR DES-ISR
p Value
(479 Patients)
(550 Lesions)
(97 Patients)
(114 Lesions)
(371 Patients)
(436 Lesions)
Age, yrs 70.0  9.9 71.0  10.1 69.7  9.9 0.20
Male 436 (79.3) 95 (83.3) 341 (78.2) 0.25
Diabetes mellitus 277 (50.4) 48 (42.1) 229 (52.5) 0.06
Hypertension 432 (78.5) 88 (77.2) 344 (78.9) 0.70
Hyperlipidemia 363 (66.0) 81 (71.1) 282 (64.7) 0.22
Current smoker 13 (2.4) 2 (1.8) 11 (2.5) >0.99
Hemodialysis 55 (10.0) 6 (5.3) 49 (11.2) 0.08
Acute coronary syndrome 48 (8.7) 10 (8.8) 38 (8.7) >0.99
Stable angina 502 (91.3) 104 (91.2) 398 (91.3) >0.99
Previous myocardial infarction 357 (64.9) 76 (66.7) 281 (64.4) 0.74
Previous bypass surgery 46 (8.4) 4 (3.5) 42 (9.6) 0.04
Target lesion 0.73
Left anterior descending 208 (37.8) 48 (42.1) 160 (36.7)
Left circumﬂex 97 (17.6) 20 (17.5) 77 (17.7)
Right 233 (42.4) 44 (38.6) 189 (43.3)
Left main trunk 12 (2.2) 2 (1.8) 10 (2.3)
Classiﬁcation of ISR <0.001
Focal margin 7 (1.3) 0 (0) 7 (1.6)
Focal body 193 (35.1) 19 (16.7) 174 (39.9)
Multifocal 20 (3.6) 2 (1.8) 18 (4.1)
Diffuse 258 (46.9) 75 (65.8) 183 (42.0)
Proliferative 33 (6.0) 11 (9.6) 22 (5.0)
Occlusive 39 (7.1) 7 (6.1) 32 (7.3)
Focal type restenosis 200 (36.4) 19 (16.7) 181 (41.5) <0.001
Non-focal-type restenosis 350 (63.6) 95 (83.3) 255 (58.5) <0.001
RCA ostial lesion 31 (5.6) 5 (4.4) 26 (6.0) 0.65
Bifurcation lesion 171 (31.1) 45 (39.5) 126 (28.9) 0.04
Stent fracture 63 (11.5) 3 (2.6) 60 (13.8) <0.001
Previous stent type
Bare-metal stent 114 (100)
Paclitaxel-eluting stent 61 (14.0)
Sirolimus-eluting stent 187 (42.9)
Zotarolimus-eluting stent 57 (13.1)
Everolimus-eluting stent 81 (18.6)
Biolimus-eluting stent 50 (11.5)
Previous stent size #2.5 mm 238 (43.3) 38 (33.3) 200 (45.9) 0.02
Pre-dilation
The use of scoring balloon 155 (28.2) 24 (21.1) 131 (30.1) 0.06
Balloon diameter, mm 2.89  0.44 2.93  0.43 2.90  0.43 0.41
Inﬂation pressure, atm 22.1  4.4 21.1  4.6 22.3  4.3 0.009
Paclitaxel-coated balloon
Balloon diameter, mm 2.91  0.43 2.94  0.47 2.88  0.43 0.19
Inﬂation pressure, atm 13.3  2.5 13.0  2.7 13.4  2.4 0.17
Quantitative coronary angiographic analysis
Pre-procedure
Percentage diameter stenosis 70.8  16.8 71.5  16.8 70.6  16.8 0.64
Minimal lumen diameter, mm 0.84  0.52 0.84  0.55 0.84  0.51 >0.99
Reference diameter, mm 2.90  0.44 2.90  0.47 2.90  0.43 0.98
Lesion length, mm 17.3  9.5 20.5  11.0 16.4  8.9 <0.001
Post-procedure
Percentage diameter stenosis 29.1  9.5 28.0  9.1 29.3  9.6 0.18
Minimal lumen diameter, mm 2.08  0.44 2.14  0.47 2.07  0.43 0.18
Acute gain, mm 1.24  0.61 1.29  0.56 1.23  0.62 0.28
Values are mean  SD or n (%).
BMS-ISR ¼ bare-metal stent restenosis; DES-ISR ¼ drug-eluting stent restenosis; ISR ¼ in-stent restenosis;
RCA ¼ right coronary artery.
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16of early and late restenosis because restenosis is
well known to be a time-related phenomenon and the
time at which restenosis is detected can be highly
inﬂuenced by physicians’ and patients’ decisions.
Stepwise multivariable logistic regression analysis
was then applied to individuate the variables inde-
pendently associated with recurrent restenosis. The
variables used in the multivariable analyses were
selected when they were shown to affect dependent
variables in univariate analysis or empirically if they
are known to have predictive values. Independent
variables are expressed as odds ratios with 95% con-
ﬁdence intervals. All p values <0.05 were considered
to be statistically signiﬁcant. JMP (version 9, SAS
Institute Inc., Cary, North Carolina) was used for all
statistical calculations.
RESULTS
BASELINE AND PROCEDURAL DATA. Table 1 shows
baseline clinical, angiographic, and procedural char-
acteristics in the BMS-ISR and DES-ISR groups. In
the DES-ISR group, 42.9% of the lesions (n ¼ 187)
originally received a sirolimus-eluting stent, 14.0%
(n ¼ 61) received a paclitaxel-eluting stent, 13.1%
(n ¼ 57) received a zotarolimus-eluting stent, 18.6%
(n ¼ 81) received an everolimus-eluting stent, and
11.5% (n ¼ 50) received a biolimus-eluting stent.
No signiﬁcant differences were found in clinical
characteristics between the 2 groups except for the
incidence of previous bypass surgery. Non-focal-
type restenosis and bifurcation lesions were more
frequent in the BMS-ISR group. Percentage diameter
stenosis (71.5  16.8% vs. 70.6  16.8%; p ¼ 0.64),
minimal lumen diameter (0.84  0.55 mm vs. 0.84 
0.51 mm; p > 0.99), and reference diameter (2.90 
0.47 mm vs. 2.90  0.43 mm; p ¼ 0.98) before the
procedure were similar for BMS-ISR and DES-ISR
lesions. Lesion length in the BMS-ISR group was
signiﬁcantly longer than that in the DES-ISR group
(20.5  11.0 mm vs. 16.4  8.9 mm; p < 0.001). Acute
gain was similar for BMS-ISR and DES-ISR lesions
(1.29  0.56 mm vs 1.23  0.62 mm; p ¼ 0.28).
ANGIOGRAPHIC OUTCOMES. Figure 1 shows a study
ﬂow chart. Angiographic outcomes and quantitative
coronary angiographic results are summarized in
Table 2. Patients lost to follow-up included patients
who died and patients who refused follow-up angi-
ography. Six-month follow-up angiography (204.3 
40.4 days; median: 187 days) was performed for 488
lesions (89%), and recurrent restenosis occurred in 13
lesions (13.0%) in the BMS-ISR group and in 82 lesions
(21.1%) in the DES-ISR group. TLR was performed for
7 lesions (7.0%) in the BMS-ISR group and 54 lesions
FIGURE 1 Study Flow Chart
468 Patients 550 In-Stent Restenosis Lesions
Bare-metal stent restenosis (BMS-ISR)
97 patients 114 lesions
Drug-eluting stent restenosis (DES-ISR)
371 patients 436 lesions
Angiographic follow-up
(at 6-12 months)
100 lesions (87.7%)
Early follow-up
Late follow-up
Angiographic follow-up
(at 6-12 months)
388 lesions (89.0%)
TLR (–)
334 Lesions
TLR (+)
54 Lesions
Angiographic follow-up
(at 18-24 months)
298 lesions (89.2%)
Clinical follow-up
(at 18-24 months)
431 lesions (98.9%)
Clinical follow-up
(at 18-24 months)
114 lesions (100%)
Angiographic follow-up
(at 18-24 months)
79 lesions (84.9%)
TLR (+)
7 Lesions
TLR (–)
93 Lesions
Paclitaxel-coated balloon angioplasty was performed in 550 in-stent restenosis lesions in 468 patients. Two serial angiographic follow-ups
were routinely planned for the patients. Early follow-up was planned at 6 months after the procedure, and late follow-up was planned at
18 months after the procedure. BMS-ISR ¼ bare-metal stent restenosis; DES-ISR ¼ drug-eluting stent restenosis; TLR ¼ target lesion
revascularization.
TABLE 2 Angiographic Outcomes
Overall
(550 Lesions)
BMS-ISR
(114 Lesions)
DES-ISR
(436 Lesions) p Value
Early angiographic follow-up 488/550 (88.7) 100/114 (87.7) 388/436 (89.0)
Percentage diameter stenosis 39.4  18.3 34.9  17.3 40.6  18.4 0.004
Minimal lumen diameter, mm 1.80  0.64 1.94  0.64 1.77  0.64 0.02
Late luminal loss, mm 0.27  0.56 0.17  0.49 0.29  0.57 0.04
Binary restenosis 95 (19.5) 13 (13.0) 82 (21.1) 0.09
TLR 61 (12.5) 7 (7.0) 54 (13.9) 0.06
Late angiographic follow-up 377/427 (88.3) 79/93 (84.9) 298/334 (89.2)
Percentage diameter stenosis 41.1  18.2 34.3  14.5 43.0  18.7 <0.001
Minimal lumen diameter, mm 1.75  0.62 1.97  0.57 1.69  0.63 <0.001
Late luminal loss, mm 0.34  0.59 0.19  0.49 0.38  0.61 0.004
Delayed late luminal loss, mm 0.19  0.46 0.09  0.29 0.22  0.50 0.004
Binary restenosis 61 (16.2) 4 (5.1) 57 (19.1) 0.002
Late restenosis 52 (13.8) 2 (2.5) 50 (16.8) <0.001
Late TLR 41 (10.9) 2 (2.5) 39 (13.1) 0.004
Values are n/N (%), mean  SD, or n (%).
TLR ¼ target lesion revascularization; other abbreviations as in Table 1.
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17(13.9%) in the DES-ISR group. Among TLR lesions at
early follow-up, 11 (18.0%) were for unstable angina,
9 (14.8%) were for effort angina, and 41 (67.2%) were
for restenosis at follow-up angiography with objec-
tive signs of ischemia. Eighteen-month follow-up
angiography (556  62 days; median: 553 days) was
performed for 377 (88%) of the remaining 427 lesions
(excluding TLR lesions), and late restenosis was
found in 2 lesions (2.5%) in the BMS-ISR group and in
50 lesions (16.8%) in the DES-ISR group (p < 0.001).
Late TLR was performed for 2 lesions (2.5%) in the
BMS-ISR group and 39 lesions (13.1%) in the DES-ISR
group. Among late TLR lesions, 5 (12.2%) were for
unstable angina, 10 (24.4%) were for effort angina,
and 26 (63.4%) were for restenosis at follow-up
angiography with objective signs of ischemia. De-
layed late lumen loss was signiﬁcantly larger in the
DES-ISR group (0.09  0.29 mm vs. 0.22  0.50 mm;
p ¼ 0.004). Early and late angiographic follow-up was
performed for 374 lesions. Figure 2A shows changes in
percentage diameter stenosis in the 2 groups. Per-
centage diameter stenosis at early follow-up and that
at late follow-up were signiﬁcantly larger in the DES-
ISR group. Figure 2B shows the cumulative frequency
distribution of delayed late lumen loss. Delayed latelumen loss was signiﬁcantly greater in the lesions
with DES-ISR group than in lesions with BMS-ISR as
indicated by a rightward shift of the cumulative fre-
quency distribution curve; however, the incidences of
FIGURE 2 BMS-ISR Versus DES-ISR
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(A) Changes in percentage diameter stenosis. (B) Cumulative frequency distribution of delayed late lumen loss. The salmon curve indicates the BMS-ISR group; the blue
curve indicates the DES-ISR group. Abbreviations as in Figure 1.
Habara et al. J A C C V O L . 6 6 , N O . 1 , 2 0 1 5
Late Restenosis After PCB Angioplasty J U L Y 7 , 2 0 1 5 : 1 4 – 2 2
18progression cases were similar in the BMS-ISR group
(59.5%) and DES-ISR group (65.1%) (p ¼ 0.36). In the
DES-ISR group, 70% of the lesions (n ¼ 305) originally
received a ﬁrst-generation DES and 30% (n ¼ 131)
received a second-generation DES. No signiﬁcant
difference was found in binary restenosis (21.8% vs.
19.5%; p ¼ 0.61), TLR (14.9% vs. 11.5%; p ¼ 0.38), or
late lumen loss (0.32  0.23 mm vs. 0.23  0.53 mm;
p ¼ 0.12) between lesions that received a ﬁrst-
generation DES and lesions that received a second-
generation DES. No signiﬁcant difference was found
in late restenosis (15.3% vs. 20.2%; p ¼ 0.30), TLR
(12.0% vs. 15.7%; p ¼ 0.38), or delayed late lumen loss
(0.18  0.42 mm vs. 0.30  0.63 mm; p ¼ 0.09) be-
tween lesions that received a ﬁrst-generation DES and
lesions that received a second-generation DES. In the
DES-ISR group, 86% of the lesions originally received
a limus-eluting stent and 14% received a paclitaxel-
eluting stent. No signiﬁcant difference was observed
in early restenosis (20.2% vs. 26.8%; p ¼ 0.29) or late
restenosis (17.2% vs. 14.3%; p ¼ 0.82).
CLINICAL OUTCOMES. Clinical follow-up at 18 months
was performed for 545 lesions (99%). There was only
1 case of target lesion thrombosis in the DES-ISR
group. The cumulative incidences of TLR, major
adverse cardiac events, and a composite of cardiac
death, myocardial infarction, or target lesion throm-
bosis are shown in Figure 3. The rates of TLR during
24-month follow-up in the BMS-ISR and DES-ISR
groups were 8.7% and 24.2%, respectively. Thecumulative incidence of TLR was signiﬁcantly lower
in the BMS-ISR group than in the DES-ISR group (log
rank: p ¼ 0.003). The rates of a composite of cardiac
death, myocardial infarction, or target lesion throm-
bosis during 24-month follow-up in the BMS-ISR and
DES-ISR groups were 1.9% and 3.1%, respectively (log
rank: p ¼ 0.8).
PREDICTORS OF RECURRENT RESTENOSIS. Table 3
shows baseline characteristics of lesions with and
those without recurrent restenosis during 24 months.
Table 4 shows results of multivariate analysis. Previ-
ous stent size #2.5 mm (odds ratio [OR]: 2.00; 95%
conﬁdence interval [CI]: 1.24 to 3.26; p ¼ 0.004),
percentage diameter stenosis after the procedure
(OR: 1.03; 95% CI: 1.01 to 1.06; p ¼ 0.007), and in-
stent occlusion lesion (OR: 2.78; 95% CI: 1.20 to
6.23; p ¼ 0.02) were independent predictors of
early restenosis. DES-ISR (OR: 6.09; 95% CI: 1.76 to
38.4; p ¼ 0.002), percentage diameter stenosis at
early follow-up (OR: 1.05; 95% CI: 1.02 to 1.08;
p ¼ 0.003), and hemodialysis (OR: 3.48; 95% CI: 1.35
to 8.59; p ¼ 0.01) were independent predictors of
late restenosis.
DISCUSSION
In the present study, we analyzed the long-term
safety and efﬁcacy of PCB angioplasty for ISR le-
sions. Our results suggest that late restenosis occurs
after PCB angioplasty for DES-ISR lesions but not for
FIGURE 3 Kaplan-Meier 2-Year Curves
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Kaplan-Meier curves at 2 years for the BMS-ISR group and the DES-ISR group for (A) target lesion revascularization, (B) major adverse cardiac events, and (C) a
composite of cardiac death, myocardial infarction, or target lesion thrombosis. The salmon curve indicates the BMS-ISR group; the blue curve indicates the DES-ISR
group. Abbreviations as in Figure 1.
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19BMS-ISR lesions and risk factors of recurrent reste-
nosis after PCB angioplasty for ISR lesions vary
depending on the period of time after the procedure
(Central Illustration).
We found that DES-ISR was associated with poorer
outcomes than those of BMS-ISR after treatment with
a PCB both in the early follow-up and late follow-up.
Delayed late lumen loss was signiﬁcantly larger in the
DES-ISR group. The extent of neointima progression
was larger in the DES-ISR group, but neointima pro-
gression was seen in both the BMS-ISR and DES-ISR
groups. Some studies have shown that DES-ISR was
associated with poorer outcomes than those of BMS-
ISR after treatment with a PCB in the early phase
(3,5). Some trials (1,2) showed that treatment of BMS-ISR with a PCB persistently reduces the incidence
of major adverse cardiac events compared with
the incidence after treatment with an uncoated bal-
loon or DES implantation during long-term follow-
up. Our results are consistent with the results of
those studies. However, there are currently no data
obtained in serial clinical and angiographic follow-
ups to support the use of a PCB for treatment of
BMS-ISR and DES-ISR. The mechanism and time
course of DES ISR might be different from those of
BMS ISR. The mechanisms of DES restenosis include
several drug-speciﬁc factors such as localized hyper-
sensitivity, nonuniform drug deposition, polymers,
and drug resistance, which have long proved to
be driving stimuli for neointimal thickening (6–8).
TABLE 3 Baseline Characteristics Among Lesions With and Without Recurrent Restenosis
Restenosis (-)
(344 Lesions)
Restenosis (þ)
(147 Lesions) p Value
Age, yrs 69.4  9.8 69.3  10.3 0.92
Male 277 (80.5) 111 (75.5) 0.23
Diabetes mellitus 174 (50.6) 73 (49.7) 0.92
Hypertension 263 (76.5) 122 (83.0) 0.12
Hyperlipidemia 223 (64.8) 99 (67.3) 0.61
Current smoker 5 (1.5) 5 (3.4) 0.17
Hemodialysis 28 (8.1) 20 (13.6) 0.07
Acute coronary syndrome 32 (9.3) 9 (6.1) 0.29
Stable angina 312 (90.7) 138 (93.9) 0.29
Previous myocardial infarction 230 (66.9) 90 (61.2) 0.26
Previous bypass surgery 28 (8.1) 11 (7.5) 0.86
Target lesion 0.27
Left anterior descending 131 (38.1) 49 (33.3)
Left circumﬂex 56 (16.3) 31 (21.1)
Right 148 (43.0) 66 (44.9)
Left main trunk 9 (2.6) 1 (0.7)
Focal-type restenosis 121 (35.2) 53 (36.1) 0.92
Nonfocal-type restenosis 223 (64.8) 94 (63.9) 0.92
In-stent occlusion lesion 16 (4.7) 14 (9.5) 0.06
RCA ostial lesion 17 (4.9) 12 (8.2) 0.21
Bifurcation lesion 106 (30.8) 44 (29.9) 0.91
Stent fracture 37 (10.8) 24 (16.3) 0.10
Previous stent type
Bare-metal stent 85 (24.7) 15 (10.2) <0.001
Drug-eluting stent 259 (75.3) 132 (89.8) <0.001
Previous stent size #2.5 mm 131 (38.1) 79 (53.7) 0.002
Quantitative coronary angiographic analysis
Pre-procedure
Percentage diameter stenosis 69.2  16.3 73.7  16.3 0.005
Minimal lumen diameter, mm 0.90  0.51 0.73  0.49 <0.001
Reference diameter, mm 2.93  0.44 2.81  0.46 0.01
Lesion length, mm 17.2  9.3 17.3  9.6 0.88
Post-procedure
Percentage diameter stenosis 28.5  9.2 31.0  9.7 0.008
Minimal lumen diameter, mm 2.12  0.43 1.96  0.46 <0.001
Acute gain, mm 1.22  0.57 1.23  0.66 0.87
Percentage diameter stenosis $35% 80 (23.3) 57 (38.8) <0.001
Values are mean  SD or n (%).
RCA ¼ right coronary artery.
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20In addition, it has been reported that neo-
atherosclerosis is a frequent ﬁnding in lesions that
have received a DES and occurs earlier than that in
lesions that have received a BMS (9). The speciﬁc re-
action of a previously implanted DES might be asso-
ciated with late restenosis after PCB angioplasty for
DES-ISR. Second-generation DES have been designed
to overcome the limitations of ﬁrst-generation DES.
Despite these advances, a recent study demonstrated
similar prevalences of neoatherosclerosis in lesions
that received a ﬁrst-generation DES and lesions
that received a second-generation DES (10). In de
novo coronary lesions, late restenosis after DESimplantation was reported (11,12), even after second-
generation DES implantation (13). In our study, 70%
of the lesions in the DES-ISR group originally
received a ﬁrst-generation DES and 30% originally
received a second-generation DES. No signiﬁcant
difference was found in late restenosis, TLR, or
delayed late lumen loss between lesions that received
a ﬁrst-generation DES and lesions that received a
second-generation DES. According to the 3-year re-
sults of the PEPCAD-DES (Treatment of DES–In-Stent
Restenosis With SeQuent Please Paclitaxel-Eluting
PTCA Catheter) trial (14), treatment of DES-ISR with
a PCB has persistently shown better outcomes than
those with an uncoated balloon. The PEPCAD-DES
trial was performed in relatively simple clinical and
angiographic scenarios. This may have been reﬂected
in the outcomes.
Our study demonstrated a higher risk of early
restenosis in smaller vessels and in-stent occlusion
lesions. One factor that is known to increase the risk
of ISR with SES restenosis is smaller vessel diameter
(15). In-stent occlusion lesions might include an
organized thrombus in the vessel. PCB can inhibit
neointimal formation by homogeneous drug transfer
to the vessel wall (16). However, an organized
thrombus might prevent the transfer of an anti-
proliferative drug to the vessel wall, and incomplete
suppression of neointimal hyperplasia might occur.
Percentage diameter stenosis after the procedure was
also an independent predictor of early restenosis.
This may be in part a result of underexpansion of a
stent because of artery recoil or neointimal hyper-
plasia. Stent underexpansion appears to be a signiﬁ-
cant cause of restenosis after DES implantation
treatment for ISR (17). Obtaining a high acute gain
might be essential for minimizing the risk of recurrent
restenosis in patients treated with a PCB for DES
restenosis. Cutting or scoring balloon angioplasty
has a potential advantage over conventional balloon
angioplasty for treatment of ISR because it surgically
incises restenotic plaques up to the metallic stent
cage, and these incisions can facilitate maximum
extrusion of the neointimal plaque (18). A scoring
balloon or cutting balloon might be a useful adjunct
device for restenosis lesions that cannot be dilated
by a conventional balloon.
In this study, hemodialysis was found to be an in-
dependent predictor of late restenosis. Previous
studies have shown increased rates of mortality,
myocardial infarction, and angiographic restenosis
in dialysis patients (19,20). Chronic kidney disease is
accompanied by systemic abnormalities (high oxida-
tive stress, endothelial dysfunction, and inﬂamma-
tory status) that can cause endothelial damage,
TABLE 4 Results of the Multivariable Analysis: Independent Predictors of Recurrent Restenosis
Restenosis (Early or Late) Early Restenosis Late Restenosis*
OR 95% CI p Value OR 95% CI p Value OR 95% CI p Value
DES-ISR 2.59 1.45–4.90 0.001 1.53 0.82–3.07 0.19 6.09 1.76–38.4 0.002
Previous stent size #2.5 mm 1.84 1.22–2.79 0.004 2.00 1.24–3.26 0.004 1.56 0.81–3.04 0.19
%DS, after the procedure 1.03 1.01–1.05 0.01 1.03 1.01–1.06 0.007 1.00 0.97–1.04 0.98
In-stent occlusion lesion 2.39 1.08–5.27 0.03 2.78 1.20–6.23 0.02 2.68 0.54–10.4 0.20
Right coronary artery ostial lesion 2.43 1.02–5.67 0.046 2.42 0.90–6.06 0.08 1.89 0.47–6.39 0.35
Hemodialysis 1.90 1.00–3.58 0.05 1.24 0.55–2.58 0.58 3.48 1.35–8.59 0.01
Stent fracture 1.18 0.64–2.15 0.58 1.34 0.68–2.57 0.39 1.16 0.41–2.95 0.77
%DS, at early follow-up — — — — — — 1.05 1.02–1.08 0.003
*The lesions used in the multivariable analyses of late restenosis were derived from lesions without restenosis at early follow-up.
%DS ¼ percentage diameter stenosis; CI ¼ conﬁdence interval; DES-ISR ¼ drug-eluting stent restenosis; OR ¼ odds ratio.
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21promote lipid proliferation, and lead to plaque
vulnerability. Intimal calciﬁcation develops in the
second decade of life, and the prevalence increases
over time (21). Late restenosis was speculated to
be associated with intimal calciﬁcation in dialysis
patients, although the mechanism responsible for
vascular calciﬁcation in dialysis patients remains
uncertain.
Percentage diameter stenosis at early follow-up
was also an independent predictor of late restenosis.
Percentage diameter stenosis was increased between
early follow-up and late follow-up (Figure 2). The
optimal time point for evaluation of PCB efﬁcacy for
ISR remains to be deﬁned. Long-term clinical andCENTRAL ILLUSTRATION Early and Late Restenosis Afte
Habara, S. et al. J Am Coll Cardiol. 2015; 66(1):14–22.
BMS-ISR ¼ bare-metal stent restenosis; DES-ISR ¼ drug-eluting stent rangiographic follow-ups after PCB angioplasty might
be needed.
STUDY LIMITATIONS. First, this was a retrospective
single-center study with observational analysis.
However, the results of this study are valuable because
we included all consecutive patients undergoing PCB
angioplasty for ISR lesions, and serial clinical and
angiographic outcomes with a high follow-up rate
were obtained. Second, scheduled follow-up angiog-
raphy might result in an increase in late TLR and lead
to overestimation of the clinical impact of delayed late
lumen loss. Third, the high proportion of hemodialysis
patients affects the outcome. Finally, we did not
perform imaging analysis using optical coherencer Paclitaxel-Coated Balloon Angioplasty
estenosis; TLR ¼ target lesion revascularization.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Patients with DES-ISR treated with PCB had worse
outcomes at late follow-up than did patients with
BMS-ISR, as assessed in terms of binary restenosis,
TLR, and delayed late lumen loss.
TRANSLATIONAL OUTLOOK: Longer-term studies
are needed to establish the optimum device type for
percutaneous coronary revascularization in patients
who develop ISR of coronary DES.
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22tomography, which might have enabled assessment of
the cause of restenosis.
CONCLUSIONS
Late restenosis occurs after PCB angioplasty for DES-
ISR lesions.
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